Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Name: Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
License: Public Domain

National Research Center for Hematology, Russia

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

primary mediastinal lymphoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 314323
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.